(RTTNews) - Klotho Neurosciences, Inc. (KLTO) has formed a strategic partnership with Maryland-based biotech firm AAVnerGene Inc., aiming to enhance the manufacturing of its gene therapy candidates using next-generation AAV vector technologies.
This collaboration is expected to significantly improve production speed, efficacy, and cost-efficiency across Klotho's pipeline, including KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for age-related conditions.
According to KLTO CEO Dr. Joseph Sinkule, AAVnerGene's proprietary platforms will help bring these therapies to the clinic faster with reduced costs and improved purity. He also noted the company's ongoing interest in expanding its portfolio with complementary longevity-focused assets.
AAVnerGene CEO Dr. Daozhan Yu highlighted that their AAVone and ATHENA platforms address two major barriers in AAV gene therapy: high drug pricing and dose-related toxicity. He expressed confidence that this synergy with Klotho would drive the development of more accessible and innovative treatments for both rare and common neurological diseases.
Sinkule added that AAVnerGene's targeted delivery methods align with KLTO's therapeutic approach of using a tissue-specific promoter to elevate Klotho protein levels in affected tissues, thus improving outcomes in neurologic and neuromuscular conditions.
KLTO currently trades at $1.3263 or 10.5250% higher on the NasdaqCM.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
